Cancer immunotherapy has been proven in recent years to be a promising strategy to enhance the strengths of the immune system of cancer patients to fight cancer. Neoantigens are the key to distinguishing cancer cells from normal cells and to stimulate the immune system to fight against cancer. Neoantigen identification is the most critical step in the development of effective antitumor vaccines for cancer immunotherapy.
Neoantigen detection is challenging. Mass Spectrometry-based neoantigen detection is an unbiased method, but requires highly sensitive and high throughput MS systems as well as large amounts of fresh patient tissue. Current NGS-based methods present advantages with outstanding performance for mutation detection, while still challenged to accurately detect somatic mutations of low allele frequency from FFPE or limited clinical biopsy samples. Lastly, the computational prediction of neoantigens remains a daunting problem.
BGI has developed a comprehensive service package for neoantigen detection, combining a highly accurate neoantigen prediction algorithm with whole paired tumor/normal exome and transcriptome sequencing protocols that are optimized for challenging FFPE or biopsy samples.
We provide a one-stop solution for neoantigen identification and tumor mutation landscape profiling for immuno-oncology research.
Why Choose BGI for Neoantigen Detection
One-stopsolution from sample processing to candidate neoantigen identification. Optional functional validation is available.
PatentedPSSMHCpan algorithm for accurate, sensitive and efficient in-silico neoantigen
Comprehensivetraining data set containing over 210,000 allele specific binders across 128 HLA
Extensive experience with sample processing and sequencing from more than 50,000 FFPE samples.
Quality: Services will be performed in laboratories that operate under CLIA/CAP quality systems.
We care for your samples from the start through to the result reporting. Highly experienced laboratory professionals follow strict quality procedures to ensure the integrity of your results.
Create a myBGI account to view all our sample and shipping documentation and to manage your project moving forwards. It's quick, free and easy!
Exome and Transcriptome Sequencing for Neoantigen prediction services will be performed with DNBSEQ or Illumina platforms.
The BGI Neoantigen prediction package includes
Tumor and normal whole exome sequencing
Tumor whole transcriptome sequencing
Tumor mutation landscape and expression profiling
Bioinformatics analysis for Neoantigen prediction
Optional Bioinformatics analysis for functional validation of Neoantigens
Sequencing Quality Standard
Guaranteed 30Gb of tumor whole exome data; 10Gb of tumor whole transcriptome data; 10Gb of normal whole exome data
Guaranteed ≥ 80% of bases with quality score of ≥ Q30
Turn Around Time
Typical 25 working days from sample QC acceptance to neoantigen prediction result
Expedited services are available, contact your local BGI specialist for details
With our patented PSSMHCpan neoantigen prediction algorithm following standard data processing and tumor variants calling, we provide highly accurate neoantigen prediction result as well as tumor mutation landscape and expression profile analysis to support your cancer research needs.
Reports and output data files are delivered in industry standard file formats: FASTQ, BAM, VCF, CNS and Excel.
Alignment to reference genome
SNV calling and annotation
Somatic InDel calling and annotation
Gene expression profiling
Gene fusion detection and annotation
Cross validation of WES and Transcriptome
Tumor mutation burden (TMB) calculation
Tumor Neoantigen burden (TNB) calculation
Further customization of Bioinformatics analysis to suit your unique project is available: Please contact your BGI technical representative
We can process your FFPE, Fresh frozen tissue, Needle biopsy, Blood, gDNA, and Total RNA, with the following general requirements: